# A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

> **NCT05145413** · PHASE3 · COMPLETED · sponsor: **Karuna Therapeutics, Inc., a Bristol Myers Squibb company** · enrollment: 396 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Xanomeline and Trospium Chloride Capsules
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05145413
- **Lead sponsor:** Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-12
- **Primary completion:** 2025-03-19
- **Final completion:** 2025-03-19
- **Target enrollment:** 396 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05145413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05145413, "A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05145413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*